Umer Raffat
Stock Analyst at Evercore ISI Group
(1.29)
# 3,420
Out of 4,869 analysts
21
Total ratings
50%
Success rate
-9.33%
Average return
Main Sectors:
Stocks Rated by Umer Raffat
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTSR Metsera | Initiates: Outperform | n/a | $29.60 | - | 1 | Feb 25, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | n/a | $15.01 | - | 1 | Jul 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Downgrades: In-Line | n/a | $5.05 | - | 2 | Mar 8, 2024 | |
| GUTS Fractyl Health | Initiates: Outperform | n/a | $2.14 | - | 1 | Feb 28, 2024 | |
| RAPT RAPT Therapeutics | Initiates: Outperform | n/a | $7.36 | - | 1 | Feb 16, 2024 | |
| ALKS Alkermes | Upgrades: Outperform | n/a | $29.09 | - | 1 | Oct 24, 2023 | |
| CNTA Centessa Pharmaceuticals | Initiates: Outperform | n/a | $12.46 | - | 1 | Jun 21, 2023 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Outperform | n/a | $16.95 | - | 1 | May 18, 2023 | |
| PHAT Phathom Pharmaceuticals | Upgrades: Outperform | n/a | $10.42 | - | 3 | May 11, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Outperform | n/a | $13.48 | - | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $34.00 | - | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $9.75 | - | 1 | Jun 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.61 | - | 1 | Mar 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $0.24 | +19,875.03% | 1 | Mar 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $289.33 | - | 2 | Jan 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $6.54 | +633.94% | 1 | Jun 30, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $107.51 | - | 1 | Feb 23, 2017 |
Metsera
Feb 25, 2025
Initiates: Outperform
Price Target: n/a
Current: $29.60
Upside: -
Spyre Therapeutics
Jul 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $15.01
Upside: -
Amylyx Pharmaceuticals
Mar 8, 2024
Downgrades: In-Line
Price Target: n/a
Current: $5.05
Upside: -
Fractyl Health
Feb 28, 2024
Initiates: Outperform
Price Target: n/a
Current: $2.14
Upside: -
RAPT Therapeutics
Feb 16, 2024
Initiates: Outperform
Price Target: n/a
Current: $7.36
Upside: -
Alkermes
Oct 24, 2023
Upgrades: Outperform
Price Target: n/a
Current: $29.09
Upside: -
Centessa Pharmaceuticals
Jun 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $12.46
Upside: -
Teva Pharmaceutical Industries
May 18, 2023
Upgrades: Outperform
Price Target: n/a
Current: $16.95
Upside: -
Phathom Pharmaceuticals
May 11, 2023
Upgrades: Outperform
Price Target: n/a
Current: $10.42
Upside: -
Mineralys Therapeutics
Mar 7, 2023
Initiates: Outperform
Price Target: n/a
Current: $13.48
Upside: -
Nov 2, 2022
Initiates: Outperform
Price Target: n/a
Current: $34.00
Upside: -
Jun 10, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.75
Upside: -
Mar 12, 2021
Initiates: Outperform
Price Target: n/a
Current: $3.61
Upside: -
Mar 3, 2021
Initiates: Outperform
Price Target: $48
Current: $0.24
Upside: +19,875.03%
Jan 21, 2020
Upgrades: Outperform
Price Target: n/a
Current: $289.33
Upside: -
Jun 30, 2017
Initiates: Outperform
Price Target: $48
Current: $6.54
Upside: +633.94%
Feb 23, 2017
Initiates: Buy
Price Target: n/a
Current: $107.51
Upside: -